These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19465880)

  • 1. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
    Domino ME; Foster EM; Vitiello B; Kratochvil CJ; Burns BJ; Silva SG; Reinecke MA; March JS
    J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):711-720. PubMed ID: 19465880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.
    Sava FA; Yates BT; Lupu V; Szentagotai A; David D
    J Clin Psychol; 2009 Jan; 65(1):36-52. PubMed ID: 19051275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treatments for adolescent depression: results from TADS.
    Domino ME; Burns BJ; Silva SG; Kratochvil CJ; Vitiello B; Reinecke MA; Mario J; March JS
    Am J Psychiatry; 2008 May; 165(5):588-96. PubMed ID: 18413703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
    Revicki DA; Siddique J; Frank L; Chung JY; Green BL; Krupnick J; Prasad M; Miranda J
    Arch Gen Psychiatry; 2005 Aug; 62(8):868-75. PubMed ID: 16061764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating a broader range of depressed adolescents with combined therapy.
    Foster S; Mohler-Kuo M
    J Affect Disord; 2018 Dec; 241():417-424. PubMed ID: 30145512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial.
    Sacristán JA; Gilaberte I; Boto B; Buesching DP; Obenchain RL; Demitrack M; Pérez Sola V; Alvarez E; Artigas F
    Int Clin Psychopharmacol; 2000 Mar; 15(2):107-13. PubMed ID: 10759342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
    Lynch FL; Dickerson JF; Clarke G; Vitiello B; Porta G; Wagner KD; Emslie G; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes T; DeBar L; McCracken JT; Strober M; Suddath RL; Spirito A; Onorato M; Zelazny J; Iyengar S; Brent D
    Arch Gen Psychiatry; 2011 Mar; 68(3):253-62. PubMed ID: 21383263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
    Lewis CC; Simons AD; Nguyen LJ; Murakami JL; Reid MW; Silva SG; March JS
    J Am Acad Child Adolesc Psychiatry; 2010 Feb; 49(2):132-40. PubMed ID: 20215935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Lenox-Smith A; Greenstreet L; Burslem K; Knight C
    Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
    Brown MC; Nimmerrichter AA; Guest JF
    Eur Psychiatry; 1999 Jul; 14(4):230-44. PubMed ID: 10572352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
    JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
    Rohde P; Silva SG; Tonev ST; Kennard BD; Vitiello B; Kratochvil CJ; Reinecke MA; Curry JF; Simons AD; March JS
    Arch Gen Psychiatry; 2008 Apr; 65(4):447-55. PubMed ID: 18391133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
    ; March J; Silva S; Curry J; Wells K; Fairbank J; Burns B; Domino M; Vitiello B; Severe J; Riedal K; Goldman M; Feeny N; Findling R; Stull S; Baab S; Weller EB; Robbins M; Weller RA; Jessani N; Waslick B; Sweeney M; Dublin R; Walkup J; Ginsburg G; Kastelic E; Koo H; Kratochvil C; May D; LaGrone R; Vaughan B; Albano AM; Hirsch GS; Podniesinki E; Chu A; Reincecke M; Leventhal B; Rogers G; Jacobs R; Pathak S; Wells J; Lavanier SA; Danielyan A; Rohde P; Simons A; Grimm J; Frank S; Emslie G; Kennard B; Hughes C; Mayes TL; Rosenberg D; Benazon N; Butkus M; Bartoi M
    Am J Psychiatry; 2009 Oct; 166(10):1141-9. PubMed ID: 19723787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of readiness to change in response to treatment of adolescent depression.
    Lewis CC; Simons AD; Silva SG; Rohde P; Small DM; Murakami JL; High RR; March JS
    J Consult Clin Psychol; 2009 Jun; 77(3):422-8. PubMed ID: 19485584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.